Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemiaGuillermo Garcia‐Manero, Jean‐Pierre J. Issa, Farhad Ravandi et al.|Blood|2006Cited by 468
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop M. Kantarjian, Susan O’Brien, Deborah A. Thomas et al.|The Lancet Oncology|2012Cited by 411
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtypeNitin Jain, Joseph D. Khoury, Audrey L. Lamb et al.|Blood|2016Cited by 346
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaHagop M. Kantarjian, Susan O’Brien, Deborah A. Thomas et al.|Cancer|2013Cited by 302